ASSEMBLY BIOSCIENCES, INC. (ASMB) SEC Filings

Assembly Biosciences, Inc. filed an amended current report to correct an administrative tagging error, clarifying that its August 13, 2026 submission relates to results of operations and financial condition. The underlying second-quarter 2026 information remains unchanged.

For the quarter ended June 30, 2026, collaboration revenue from Gilead rose to $13.4 million, while research and development expense declined to $14.9 million and general and administrative expense was $4.8 million. Net loss narrowed to $3.9 million, or $0.20 per share. Cash, cash equivalents and marketable securities totaled $320.4 million, supported by a recently completed $115 million gross financing and a collaboration extension payment from Gilead that together are projected to fund operations into 2029.

Operationally, Assembly expanded ABI-6250 into cholestatic liver diseases with Phase 2 studies in hepatitis delta virus and cholestatic indications planned between late 2026 and early 2027. In its partnered herpes program, GS-1179 was selected to advance, with a Phase 2 trial in recurrent genital herpes expected to start by year-end 2026 and a potential role alongside HIV PrEP under consideration.

Assembly Biosciences, Inc. is a biotechnology company focused on therapeutics for serious viral and liver diseases, including recurrent genital herpes, hepatitis delta virus (HDV), cholestatic liver diseases, hepatitis B virus (HBV) and transplant‑related herpesviruses. For the quarter ended June 30, 2026, collaboration revenue from its related‑party agreement with Gilead Sciences was $13.4 million, up from $9.6 million a year earlier, while research and development and general and administrative expenses totaled $19.7 million, slightly below the prior‑year quarter. Net loss narrowed to $3.9 million for the quarter and $12.9 million for the first six months of 2026, compared with $10.2 million and $19.0 million in the respective 2025 periods, aided by $4.8 million of interest and other income in the first half.

Cash, cash equivalents and marketable securities were $320.4 million as of June 30, 2026, and management states this is sufficient to meet operating requirements for more than one year. During the first half, the company completed an underwritten offering of common stock and pre‑funded warrants providing net proceeds of about $108.1 million, increasing stockholders’ equity to $305.6 million. The Gilead collaboration continues to be central, with $21.6 million of first‑half collaboration revenue, an exercised option and exclusive license for the helicase‑primase inhibitor program, and ongoing eligibility for milestones and royalties across multiple programs.

Assembly Biosciences reported second quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $320.4 million as of June 30, 2026, helped by a recently completed $115 million gross financing and collaboration funding from Gilead, and are projected to fund operations into 2029, including a $75 million Gilead extension payment expected in the fourth quarter of 2026.

Collaboration revenue from Gilead rose to $13.4 million from $9.6 million a year earlier, while research and development expenses declined to $14.9 million from $16.1 million. Net loss narrowed to $3.9 million, or $0.20 per share, compared with $10.2 million, or $1.33 per share, reflecting higher revenue, lower R&D and higher interest income.

Strategically, the company expanded ABI-6250 into cholestatic liver diseases with a Phase 2 study planned in early 2027 and plans Phase 2 trials in chronic HDV and cholestatic liver diseases by late 2026 and early 2027. Gilead selected GS-1179 (HSV helicase‑primase inhibitor) to move into Phase 2 by year-end 2026, with Assembly Biosciences evaluating whether to opt into a 40% U.S. cost‑profit share.

Assembly Biosciences, Inc. reports that Janus Henderson Group Ltd., as parent of multiple affiliated asset managers, is deemed the beneficial owner of 1,359,514 shares of common stock, including shares obtainable through warrant exercises. This position represents 6.9% of Assembly Biosciences’ common stock. Janus Henderson has no sole voting or dispositive power over these shares but holds shared voting and shared dispositive power over 1,359,514 shares through its asset manager subsidiaries, which exercise investment and/or voting discretion for their clients’ managed portfolios. The managed portfolios retain the right to receive all dividends and sale proceeds, and the filing notes that only Janus Henderson Biotech Innovation Master Fund Ltd. has rights to more than five percent of the common stock, but is not a separate reporting person due to an irrevocable delegation of investment and voting discretion.

Assembly Biosciences, Inc. is reported to have 1,604,590 shares of common stock beneficially owned by investment partnerships managed by Farallon Capital Management, L.L.C., representing 8.1% of the outstanding shares. These holdings are attributed to several Farallon funds, while Farallon Capital Management and named managing members are reporting persons by virtue of their roles.

In addition, the Farallon funds hold 510,205 Class A Warrants, currently exercisable subject to limits, and 510,205 Class B Warrants, exercisable beginning on November 15, 2026. Each warrant is exercisable for one share, but a 4.99% Beneficial Ownership Limitation prevents exercises that would take the group’s beneficial ownership above that threshold. As a result, the 1,020,410 warrants are treated as not exercisable within 60 days and are excluded from the reported 8.1% beneficial ownership. The Farallon funds have the right to receive dividends and sale proceeds on the securities they hold.

ASSEMBLY BIOSCIENCES, INC. principal financial and accounting officer Jeanette M. Bjorkquist reported a small sale of 29 shares of common stock at $23.25 per share. The sale was executed solely to cover tax withholding on vested restricted stock units under a mandatory sell-to-cover rule, and she still holds 14,560 shares directly.

Gaggar Anuj reported acquisition or exercise transactions in this Form 4 filing.

Assembly Biosciences Chief Medical Officer Anuj Gaggar reported an equity compensation grant in the form of 14,000 shares of common stock at a price of $0.00 per share. These shares reflect restricted stock units that became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.

The RSUs vest in four approximately equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service. Following this award and prior ESPP purchases, Gaggar now holds 42,688 common shares directly, indicating a routine compensation-related increase in ownership.

White Nicole S reported acquisition or exercise transactions in this Form 4 filing.

Assembly Biosciences reported that Chief Manufacturing Officer Nicole S. White received a grant of 14,000 shares of common stock in the form of restricted stock units as part of her annual equity compensation. The RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.

The RSUs vest in four approximately equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming she remains in continuous service. Following this grant and an administrative correction that removed 3,332 shares from prior totals, she now directly holds 48,145 shares of common stock.

Assembly Biosciences director John G. McHutchison received a grant of stock options for 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders.